Hans H. Zingg

Hans Zingg Hans H. Zingg, M.D., Ph.D.

Professor Emeritus, Departments of Medicine, Pharmacology and Obstetrics & Gynecology
326 Brock Avenue North, Montreal-West, H4X 2G5

Tel: 514-487-3565

hans.zingg [at] mcgill.ca

Biographical Sketch

Dr. Zingg received his MD in 1973 at the University of Basel and his Ph.D. at McGill under the guidance of the late Dr. Y. C. Patel. After a postdoctoral fellowship at Harvard Medical School with Dr. Joel Habener, he was recruited back to McGill where he rose to the ranks of Full Professor of Medicine, Pharmacology and Obstetrics & Gynecology. Prior to being Chairman of the Department of Pharmacology and Therapeutics, he was Director of the Laboratory of Molecular Endocrinology at the Royal Victoria Hospital and Associate Director, Fundamental Research, of the MUHC Research Institute. He was the holder of a Wyeth-Ayerst Clinical Research Chair, a Distinguished Scientist Award from the Canadian Society for Clinical Investigations and a Senior Scientist Award from the CIHR. He is a member of the American Association of Physicians (AAP).


Endocrine disorders, diabetes mellitus, obesity, oxytocin mechanisms of action, GPCR signaling

Research or Clinical Activities

Research contributions include the discovery of a novel paracrine oxytocin system in the uterus, novel direct interactions between steroid hormones and peptide hormone receptors, cloning of the rat oxytocin receptor gene, characterization of oxytocin receptor-associated signaling mechanisms and discovery of novel genes expressed in the uterus.

Dr. Zingg is actively involved in teaching medical students basic concepts in endocrinology and selected clinical skills. He is also seeing patients at the Metabolic Day Centre of the MUHC.

Selected Recent Publications

Devost D., Carrier M-E, and Zingg H.H. 2008 Oxytocin-induced activation of eukaryotic elongation factor eEF2 in myometrial cells is mediated by protein kinase C. Endocrinology 149:131-138.

Goupil E, Tassy D, Bourguet C, Quiniou C, Wisehart V, Pétrin D, Le Gouill C, Devost D, Zingg HH, Bouvier M, Saragovi HU, Chemtob S, Lubell WD, Claing A, Hébert TE, Laporte SA. 2010 A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2alpha-mediated Rho/ROCK signaling pathway. J Biol Chem.285:25624-36.

Murat B, Devost D, Andres M, Mion J, Boulay V, Corbani M, Zingg HH, Guillon G 2012 V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH. Molecular Endocrinology 26:502-20, Elected to the Faculty of 1000 (http://f1000.com/714897825)

Wrzal P, Hebert TE, Zingg HH 2012 Functional interactions between the oxytocin receptor and the β2-adrenergic receptor: implications for ERK1/2 activation in human myometrial cells. Cell Signaling 24:333-41

Wrzal P, Zingg HH, Hebert TE 2012 Allosteric interactions between the oxytocin receptor and the β2-adrenergic receptor in the modulation of ERK1/2 activation are mediated by heterodimerization. Cell Signaling 24:342-50

PubMed Publications –  H. Zingg


Back to top